Latest Blog Posts Tagged "LRRK2"
January 18, 2018
This connection, published by researchers from Mount Sinai in New York City, may help better understand and treat these diseases.
January 12, 2018
Michael J. Fox Foundation-funded researchers have created exquisitely sensitive antibodies that may help test therapies against a top Parkinson's drug target.
December 21, 2017
Denali Therapeutics announced its first-in-human LRRK2 inhibitor is safe and lowers LRRK2 protein activity in humans' body cells, meaningful milestones for this potentially disease-modifying therapy.
August 15, 2017
The launch of key Parkinson's protein LRRK2 into space inspires a Patient Council member's actions in pursuit of a cure and his daughter's curiosity around research.
July 20, 2017
MJFF is partnering to send LRRK2 protein to the International Space Station to grow larger LRRK2 crystals, which can help develop therapies. Michael J. Fox shares a special message on this project.
April 07, 2017
A recent study, funded in part by The Michael J. Fox Foundation, examined the role of LRRK2 in the immune cells in blood of people with sporadic PD and healthy individuals.
February 06, 2017
Barbara and Jay Robinson discuss their decision to participate in Parkinson's genetics research.
November 22, 2016
For Jessica O'Brien, Facebook was a place to post pictures of her dogs, until it became a starting point in her journey to understand Parkinson's disease.
October 26, 2016
An MJFF-funded study identified a new factor that may affect age of PD onset in individuals who carry a LRRK2 mutation.
October 11, 2016
In this podcast, MJFF staff scientist Marco Baptista, PhD, discusses the genetics and biology of LRRK2 and the role of the Foundation in advancing development of LRRK2 therapeutics.